1. Home
  2. KREF vs OMER Comparison

KREF vs OMER Comparison

Compare KREF & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KKR Real Estate Finance Trust Inc.

KREF

KKR Real Estate Finance Trust Inc.

N/A

Current Price

$8.44

Market Cap

623.9M

Sector

Real Estate

ML Signal

N/A

Logo Omeros Corporation

OMER

Omeros Corporation

N/A

Current Price

$10.99

Market Cap

628.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KREF
OMER
Founded
2014
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
623.9M
628.9M
IPO Year
2017
2009

Fundamental Metrics

Financial Performance
Metric
KREF
OMER
Price
$8.44
$10.99
Analyst Decision
Buy
Strong Buy
Analyst Count
6
5
Target Price
$10.71
$27.50
AVG Volume (30 Days)
843.1K
1.7M
Earning Date
10-21-2025
11-13-2025
Dividend Yield
11.79%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$62,012,000.00
N/A
Revenue This Year
$16.86
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.78
$2.95
52 Week High
$11.74
$13.60

Technical Indicators

Market Signals
Indicator
KREF
OMER
Relative Strength Index (RSI) 53.59 71.19
Support Level $8.38 $9.31
Resistance Level $8.63 $11.03
Average True Range (ATR) 0.17 0.73
MACD 0.04 0.18
Stochastic Oscillator 70.34 97.89

Price Performance

Historical Comparison
KREF
OMER

About KREF KKR Real Estate Finance Trust Inc.

KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: